Roche affiliate Chugai Pharmaceutical Co., Ltd. appears to be taking pre-emptive action in India to block alleged infringement activity pertaining to its lung cancer therapy Alecensa (alectinib).
Chugai Pursues Alecensa Patent Infringement Charges In India
Roche affiliate Chugai has moved court in India seeking to restrain Natco and MSN Laboratories over alleged infringement of its patent concerning Alecensa. The Indian firms, however, contend their actions fall under the ambit of the country’s “Bolar exemption” provision.
